Webinar: Secondary Prevention of Cardiovascular Events in Patients with Obesity

Please join the MAOFP obesity work group for a virtual journal club, “Secondary Prevention of Cardiovascular Events in Patients with Obesity” on Tuesday, May 14th from 7:00PM-8:00PM EDT.

The session will include a brief overview of the new semaglutide 2.4 mg cardiovascular indication and the evidence that informed this clinical update from Kristin Hoddy, PhD, RD with Novo Nordisk Medical Affairs. A forum for robust discussion will follow.

Continuing education credit will not be available.

Dr. Kristin Hoddy, PhD, RD is an obesity subject matter expert with training in exercise science and dietetics. Complementing a decade of clinical research in obesity and lifestyle-based weight management interventions, she also has experience from the health and fitness industry as a former performance consultant and corporate wellness director. Kristin is passionate about bringing awareness to the importance of obesity care. As an Obesity Medical Liaison with Novo Nordisk, she strives to be a resource for scientific information and aims to support obesity champions in their efforts to advance cardiometabolic care.